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Abstract
Background: Protein aggregation correlates with the development of several debilitating human
disorders of growing incidence, such as Alzheimer's and Parkinson's diseases. On the
biotechnological side, protein production is often hampered by the accumulation of recombinant
proteins into aggregates. Thus, the development of methods to anticipate the aggregation
properties of polypeptides is receiving increasing attention. AGGRESCAN is a web-based software
for the prediction of aggregation-prone segments in protein sequences, the analysis of the effect of
mutations on protein aggregation propensities and the comparison of the aggregation properties
of different proteins or protein sets.
Results: AGGRESCAN is based on an aggregation-propensity scale for natural amino acids derived
from in vivo experiments and on the assumption that short and specific sequence stretches
modulate protein aggregation. The algorithm is shown to identify a series of protein fragments
involved in the aggregation of disease-related proteins and to predict the effect of genetic mutations
on their deposition propensities. It also provides new insights into the differential aggregation
properties displayed by globular proteins, natively unfolded polypeptides, amyloidogenic proteins
and proteins found in bacterial inclusion bodies.
Conclusion: By identifying aggregation-prone segments in proteins, AGGRESCAN http://
bioinf.uab.es/aggrescan/ shall facilitate (i) the identification of possible therapeutic targets for anti-
depositional strategies in conformational diseases and (ii) the anticipation of aggregation
phenomena during storage or recombinant production of bioactive polypeptides or polypeptide
sets.
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Protein aggregation has become a key topic in both bio-
technological and medical sciences [1,2]. It constitutes the
main bottleneck in protein production, narrowing the
spectrum of relevant polypeptides obtained by recom-
binant techniques [3]; it reduces the shelf life and
increases the immunogenicity of polypeptidic drugs [4];
and it is associated with an increasing number of critical
human diseases including Alzheimer's disease, spongi-
form encephalopaties, type II diabetes mellitus and Par-
kinson's disease [5-8].
In the last decade data have begun to accumulate suggest-
ing that the composition and the primary structure of a
polypeptide determine to a large extent its propensity to
aggregate and that small changes may have a huge impact
on solubility. The ability to predict the aggregation pro-
pensity of a protein from its sequence would be of much
value, for example, in the control of unwanted protein
deposition events through specific sequence targeted ther-
apeutics or in the discovery of more soluble variants of
proteins of biotechnological interest. It is commonly
assumed that not all regions of a polypeptide are equally
important in determining its aggregation tendency. In this
context, some authors have recently proved that very short
specific amino acid stretches can act as facilitators or
inhibitors of amyloid fibril formation [9,10]. These rele-
vant regions are usually known as aggregation "hot spots"
(HS) and their presence has been described in most of the
peptides and proteins underlying neurodegenerative and
systemic amyloidogenic disorders [11].
In previous work we exploited the experimental data
obtained from a system in vivo that uses the β-amyloid
peptide as model to derive a simple approach for the
detection of "hot spots" of aggregation [12,13]. This
approach permitted the identification of aggregation-
prone segments in several unstructured and globular dis-
ease-linked polypeptides and the prediction of the effect
of disease-linked mutations in some of these polypep-
tides. Here, we describe a software and web interface
(AGGRESCAN) that implement this approach and extend
it to the general prediction of aggregation "hot spots" and
the evaluation of their contribution to the differential
aggregation behaviour of polypeptides. In addition to
enabling the simultaneous analysis of a large number of
sequences, AGGRESCAN introduces a new set of func-
tions and descriptors for the identification of "hot spots"
of aggregation and the determination of their relevance
within the parent sequence.
Implementation
Approach
Recent findings in the study of protein aggregation indi-
cate that not all the polypeptides share the same aggrega-
tion propensities and that there exists specific continuous
protein segments that can nucleate the aggregation proc-
ess when exposed to solvent [9,10], suggesting a
sequence-dependence of aggregation propensities. At the
same time, it has been shown that the same physicochem-
ical principles underlie the aggregation propensities of
different polypeptides from unfolded states [14]. Accord-
ing to these assumptions one may expect that the conclu-
sions obtained from the study of a relevant nucleating
sequence, or "hot spot" of aggregation, in its natural
polypeptidic context could apply to other unrelated pro-
teins. Using an in vivo reporter method to study a "hot
spot" in the central hydrophobic core of Aβ we calculated
the effect of single point mutations on the aggregation
propensities of the peptide within the cell. The results
were used to approximate the in vivo intrinsic aggregation
propensities of natural amino acids when located in an
aggregation-prone sequence stretch [12] (see additional
file 1). This information was subsequently used to gener-
ate an aggregation profile for any protein sequence under
study to detect those regions with high aggregation pro-
pensities. Comparison of the theoretically calculated
changes in aggregation propensities between a wild type
sequence and different mutants serves also as a tool to
predict the behavior of the mutant forms. Albeit the basic
simplicity of this phenomenological model, it predicts, at
least qualitatively, both the presence of experimentally
validated "hot spots" and the variations in aggregation
propensity introduced by mutations in some disease-
related polypeptides [13].
System description
AGGRESCAN is a web-based tool with a computing core
coded in C and a front end written in a combination of
html and perl cgi. Development of AGGRESCAN was car-
ried out under Mandriva Linux LE2005 and the service is
currently running under Mandrake Linux 9.0 on a Pen-
tium 4 1300 MHz (willamette) with 1GB RDRAM.
For each polypeptide sequence input, AGGRESCAN calcu-
lates and reports: i) an aggregation-propensity value for
each residue in the sequence and a graphical representa-
tion of the profile for the entire polypeptide; ii) the areas
of profile peaks over a precalculated threshold and a
graphical representation of peak-area values; iii) putative
aggregation "hot spots", identified from the polypeptide's
aggregation profile.
Input
The polypeptide sequence(s) can be typed or pasted on
screen using FASTA format. Despite supporting up to 100
characters for name entries, use of very long names is dis-
couraged as it disturbs the visualization of the output.
Sequence entries may not contain more than 2,000 resi-
dues and the letters must correspond to those associatedPage 2 of 17
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not satisfied an error message will appear on screen.
White-space, enter and tab characters are ignored. Charac-
ters may be entered as lower and/or upper case, and so
will remain in the output.
Processing
The calculations are based on aggregation-propensity val-
ues per amino acid (aaAV, or a3v) derived previously from
experimental data [12]. The program calculates the a3v
average (a4v) over a sliding window of a given length and
assigns it to the central residue in the window. The size of
the sliding window ([5,7,9], and [11] residues) was
trained against a database of 57 amyloidogenic proteins,
in which the location of "hot spots" was experimentally
known. In general, the predictions of the overall aggrega-
tion-prone regions do not depend on the length of the
used windows and only slightly affect their limits. There
are, however, two remarkable exceptions: 1) The use of
long windows on top of very short sequences results on
excessive smoothing of the profile and experimentally dif-
ferent "hot spots" become grouped and masked and can-
not be individualized in the prediction. 2) The use of
short windows on top of very long sequences results in the
appearance of a number of short experimentally non-rel-
evant predicted "hot spots" with associated low areas.
Thus, the procedure incorporates a ponderation of the
window length relative to the size of the analyzed protein.
The best predictions were obtained using a window size of
5 for < = 75 residues, 7 for < = 175, 9 for < = 300 and 11
for > 300, respectively, probably reflecting that for longer
sequences larger "hot spots" are necessary in order to sig-
nificantly increase their aggregation propensities, while
short-stretches suffice for smaller peptides. To account for
charge effects at the polypeptide's termini (NH3 + and
COO-) a virtual residue is added to each side of the chain
(residue 0 at the N-terminus and residue n+1 at the C-ter-
minus, n being the original sequence length). The a3v of
residue 0 equals the average a3v of the basic residues (K,
R), while that of residue n+1 equals the average a3v of the
acidic residues (D, E). The first window, ranging from res-
idue 0 to residue 4, 6, 8 or 10 (depending on window
size), will serve to assign an a4v to residue 2, 3, 4 or 5,
respectively. Thus, the off-centre residues 1, 1–2, 1–3 or
1–4 may not have an associated a4v. This is solved by giv-
ing these residues the value corresponding to the first win-
dow centre. The same procedure is followed at the C-
terminus. The "hot spot" threshold (HST) has been
defined as the average of the a3v of the 20 amino acids
weighted by their frequencies in the SwissProt database
[15]. The aggregation profile (AP) of the polypeptide is
defined by the complete sequence of a4v. The sum of a4v
and the average of a3v over the entire sequence (a4vSS and
a3vSA, respectively) are also calculated. A region in the
polypeptide sequence is considered an aggregation "hot
spot" (HS) if there are 5 or more sequentially continuous
residues with an a4v larger than the HST and none of them
is a proline (aggregation breaker) [16]. The average a4v in
each "hot spot" is then calculated (a4vAHS). Finally, the
area of the AP above the HST (AAT), the total area (TA,
HST being the zero axis), and the area above the HST of
each profile peak identified as "hot spot" (HSA) are inte-
grated numerically using the trapezoidal rule (see addi-
tional file 2).
Output
With current service resources, the delay time between
pressing the submit button and receiving the output on
screen is of 10 minutes for an input set of 100 sequences
of sizes between 40 and 1,000 residues. The output is
structured in tables, one per sequence and an additional
one with averages over all sequences, an excel-readable
document with output values and a list of sequences
sorted by normalized a4vSS for 100 residues (Na4vSS).
The first row in the output contains the sequence names.
The second row displays links to the three graphics pro-
duced per sequence, i.e., Profile graphic: AP (red), a3vSA
(green), HST (blue); Area graphic: HSA (same value
assigned to all residues in the "hot spot"); Normalized-
Area graphic: normalized HSA for a 100-residue "hot
spot" (NHSA). In the following rows we find the a3vSA,
the number of "hot spots" identified (nHS), the normal-
ized number of "hot spots" for 100 residues (NnHS), the
AAT, the THSA, the TA, the AAT and THSA divided by the
number of residues (AATr and THSAr, respectively), and
Na4vSS. Finally, a row per residue is given with columns
for the residue number, its one-letter code, a4v, HSA,
NHSA, and a4vAHS (see additional file 3).
Results and Discussion
AGGRESCAN capabilities: Validation and Examples
Generation of protein aggregation profiles and prediction of 
aggregation "hot spots"
The prediction method implemented in AGGRESCAN has
already allowed the identification of experimentally
proved "hot spots" (HSs) in a set of both natively
unfolded and globular pathogenic proteins: Aβ42 pep-
tide, synuclein, amylin, prion protein, transthyretin, β2-
microglobulin and lysozyme [12]. The main aims in the
design of AGGRESCAN were the automation of this anal-
ysis for the study of large sets of polypeptide sequences,
the introduction of new variables in the postprocessing of
the aggregation profiles to provide a set of values that
could be easily correlated with aggregation propensities
and the presentation of results in a convenient and
informative way. To further prove the general predictive
ability of the method, the above-mentioned proteins,
together with a new set of well studied protein sequences
related to depositional diseases (aDan, aBri, apolipopro-
teins AI, AII, AIV, and CII, prolactin, insulin, Tau, fibrino-Page 3 of 17
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tropoelastin and medin), or shown to form amyloid in
vitro (myoglobin, glycophorin A and amphoterin) have
been analyzed with AGGRESCAN (Table 1). The predicted
aggregation-prone protein regions have been validated by
comparison to available experimental data on (i) regions
known to promote aggregation, (ii) fragments known to
aggregate in vivo (often after proteolysis) and (iii) syn-
thetic short peptides shown to aggregate in vitro (refer-
ences in Table 1). In the AGGRESCAN output, the
sequence stretches with highest predicted aggregation pro-
pensity are shown in red in the peptide sequence column
and appear as peaks in the Profile plots. The HS can be
ranked according to their peak area (HSA) or normalized
peak area (NHSA). Interestingly, protein segments that are
experimentally known to be involved in aggregation are
also found among the top ranked HS in their respective
sequences based of the approach described here (Table 1),
indicating that AGGRESCAN catches the main features
underlying deposition in many conformational diseases.
These results, together with previous experimental [10,17-
20] and theoretical [21-24] data, suggest that specific
short polypeptide stretches effectively promote and/or
modulate protein amyloid formation.
One remarkable example in the test set is lung surfactant
protein C (SP-C). This protein is expressed as a 197-amino
acid proprotein that is processed to the 35-amino acid
mature peptide. This fragment is associated with the
development of pulmonary alveolar proteinosis (PAP).
The bronchoalveolar fluid from PAP patients is rich in
insoluble SP-C aggregates which exhibit the characteristic
properties of amyloids by Congo red staining and electron
microscopy. Moreover, the isolated peptide has been
shown to form amyloid fibrils in vitro [25]. In good agree-
ment with this data, AGGRESCAN predicts the SP-C
region within the precursor as the HS with the highest
aggregation propensity (Figure 1).
Other two interesting molecules are serum amyloid A
(SAA) and Tau proteins, involved in systemic amyloidosis
and Alzheimer's disease, respectively. AGGRESCAN
detects only one HS in SAA and a very dominant one in
Tau (Figure 1). In both cases, these sequence stretches cor-
respond to the unique regions in SAA and Tau proved to
be relevant for amyloidosis [26,27]. Importantly, the SAA
and Tau sequences display highly negative Na4vSS values,
-28.2 and -32.5 respectively. Although this suggests an
overall low aggregation propensity, the presence of spe-
cific HS that can act as nucleation points from which the
ordered fibrillar structure can be expanded under certain
circumstances, turn these proteins amyloidogenic. Actu-
ally, Tau is an usually highly soluble microtubule-associ-
ated protein [28] but in Alzheimer's disease it aggregates
into fibres with a tendency to form neurofibrillary tangles.
To date, only few 3D structures of amyloid assemblies at
atomic resolution are available [29]. A crucial question is
whether the formation of the tightly packed β-sheets
observed in these structures is a generic backbone prop-
erty or is dictated by the sequence. Interestingly enough,
AGGRESCAN detects the presence of "hot spots" in most
of the strands forming the intimate structure of the differ-
ent protein fibrils (Table 2), providing additional support
for the relevance of the primary structure on amyloid for-
mation.
There are several computational approaches for detecting
aggregation-prone regions and predicting polypeptide
propensities for amyloid fibril formation. Some of them,
including AGGRESCAN, rely on experimental or theoreti-
cal calculations of individual amino acid aggregation pro-
pensities and on the use of these values to scan protein
sequences. The main difference between these algorithms
is the way aggregation propensities are obtained. Pawar
and co-workers proposed an aggregation scale based on
phenomenological expressions relating protein intrinsic
factors with the aggregation rates of a set point mutants
scattered along acylphosphatase sequence and of a few
other polypeptides [30]. As the fitting was done consider-
ing effects in both aggregation relevant and non-relevant
regions, it is possible that the data do not necessarily
reflect propensities within nucleating sequences. To
address this point, Rojas Quijano and co-workers derived
propensities from the analysis of the Tau-related amy-
loidogenic peptide Ac-VQIVYK-amide and its single site
mutants Ac-VQIVXK-amide (X≠Cys) [19]. In AGGRES-
CAN, we somehow combine both approaches, in the
sense that (i) propensities are calculated from the analysis
of single mutants in a nucleating sequence (the central
hydrophobic cluster of Aβ) which is perhaps the best well
characterized aggregation-prone sequence in the literature
and one of the few for which a high-resolution structure
in the amyloid conformation is available, and (ii) we con-
sider it in the context of the full length polypeptide (in fact
fused to GFP, which acts as aggregation reporter) and not
in an isolated manner as a short peptide. In addition, to
the best of our knowledge our method is the only one in
which aggregation propensities have been derived from
experiments inside the cell, where the presence of the
folding machinery might modulate the aggregation ten-
dencies of polypeptides. Besides these three experimen-
tally calculated propensity scales, Galzitskaya and co-
workers have used the mean packing density for natural
amino acid residues in protein structures, as a scale to pre-
dict amyloidogenic regions in proteins [31]. A compara-
tive analysis of the four different scales shows that, despite
these differences, there is a striking correlation between
our in vivo obtained amino acid aggregation propensities
and the others (Table 3), probably because they reflect a
combination of properties characteristic of protein aggre-Page 4 of 17
(page number not for citation purposes)
BMC Bioinformatics 2007, 8:65 http://www.biomedcentral.com/1471-2105/8/65
Page 5 of 17
(page number not for citation purposes)
Table 1: List and ranking of the predicted aggregation-prone regions in the different disease-linked polypeptides analyzed in this study 
and comparison with the available experimental data.
Protein Experimental regiona Predicted regionb Rankingc References
Abri 1–34 4–9 2/2 [52]
15–28 1/2
Adan 1–34 4–9 2/2 [53]
15–24 1/2
68–78 66–77 1/6 [54–56]
α-Synuclein 31–109 36–42 2/6 [56]
49–55 4/6
87–94 5/6
Amphoterin 12–27 14–22 2/3 [57]
Amyloid-β-protein 17–21 17–22 2/2 [58]
31–36/38–42 30–42 1/2
Apoliprotein A-I 1–83 13–21 2/2 [59]
Apoliprotein A-II N-terminal fragments 1–19 1/3 [11]
Apoliprotein A-IV N-terminal fragments 1–19 1/6 [11]
Apoliprotein C-II 57–74 60–67 2/3 [60]
69–76 1/3
β2-Microgobulin 21–41 22–30 2/2 [61]
59–79 59–70 1/2 [62]
Exon 30 Tropoelastin 1–25 1–7 2/2 [63]
9/18 1/2
Fibrinogen A α-chain 501–506 499–521 1/6 [64]
482–504 501–506 1/5
Glycophorin A 70–98 74–98 1/4 [65]
Insulin 1–38 12–19 1/3 [66]
21–27 3/3
Islet amyloid 
polypeptide
8–20 13–18 1/2 [67]
20–29 24–28 2/2 [68]
Lysozyme (Hen) 40–64 54–62 2/4 [69]
49–101 76–84 3/4 [70]
Medin 47–54 49–55 1/3 [71]
Myoglobin (Horse) 101–118 101–115 1/4 [72]
Prion Protein 106–147 117–136 3/6 [73]
138–142 6/6
Prolactin 1–34 10–32 2/9 [74]
Pulmonary surfactant 
protein
24–58 31–59 1/5 [25]
Serum Amyloid A 2–12 1–9 1/2 [75]
Tau 301–320 304–311 1/2 [27]
10–20 12–19 2/7 [76]
Transthyretin 105–115 105–112 3/7 [77]
114–123 4/7
aSequence stretches experimentally identified as critical for protein aggregation.
bCoincident aggregation-prone segments as predicted by AGGRESCAN.
cThe rank position refers to the entire protein and reflects the importance of this specific "hot spot" (HS) relative to all the aggregation-prone 
regions identified by AGGRESCAN in the protein. (i.e., 1/4 indicates that this HS has the highest aggregation propensity of the four detected in a 
particular sequence by the software)
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Hot spot area graphicsFigure 1
Hot spot area graphics. Hot spot area plots for a) lung surfactant protein C, b) serum amyloid A protein and c) Tau protein.
A
C
B
BMC Bioinformatics 2007, 8:65 http://www.biomedcentral.com/1471-2105/8/65gation, such as hydrophobicity, secondary structure pro-
pensity or packing density. Importantly, although our
method was not aimed at the specific identification of
short amyloidogenic peptides, but rather of aggregation-
prone sequences within natural proteins, AGGRESCAN
identifies the presence of at least one hot spot in more
than 80% of the amyloid forming sequences in a set of
experimentally characterized peptide fragments of amy-
loidogenic proteins [32]. Also, using a database of six-res-
idue peptides containing both amyloid formers and non-
formers [32,33] the receiver operator characteristic (ROC)
curve for our method compares well with those obtained
using structure-based data, such us packing density on
protein structures or the 3D profile method, based on the
threading of six-residue peptides through the known crys-
tal structure of the cross-β spine formed by the peptide
NNQQNY from Sup35 yeast prion [32] (Figure 2).
Overall, the success of different computational
approaches in predicting aggregation-prone regions
allows to propose that aggregation propensity in polypep-
tide chains is ultimately dictated by the sequence. As it
happens with the native conformation of proteins, the
sequence contains intrinsic information that is relevant
for the regular structural arrangement within β-aggregates,
implying that the mechanism of amyloid fibril formation
is similar for different peptides and proteins.
Prediction of the effects of protein mutation on the aggregation 
propensity
Aggregation propensity varies sensibly with the composi-
tion and especially the sequence of the polypeptide, in
such a way that single amino acid substitutions in pro-
teins associated to depositional diseases result in many
cases in changes in the global protein aggregation propen-
sity and sometimes lead to premature or acute pathologi-
cal symptoms. Predicting the effect of a mutation on the
aggregation tendency of a protein could help to anticipate
the implications of that mutation in disease development
or assist the design, production and storage of more solu-
ble variants of biotechnologically relevant proteins and
peptides [34].
Several AGGRESCAN output variables can be used to pre-
dict the effect of sequence variations on the aggregation
propensities of a given polypeptide. The change in the
normalized a4v sum (Na4vSS) and Total Area (TA) are
obvious indicators of changes in aggregation properties of
the complete sequence due to point mutations. Neverthe-
less, a mutation will not always affect significantly the glo-
Table 3: Correlation coefficients (R) between the individual amino acid aggregation propensities used by AGGRESCAN and those used 
by other predictive methods.
AGGRESCAN AMYLOID1a AMILOYD2b AMYLOID3c
AGGRESCAN * 0.849 0.794 0.867
AMYLOID1a 0.849 * 0.764 0.837
AMILOYD2b 0.794 0.764 * 0.807
AMYLOID3c 0.867 0.837 0.807 *
a AMYLOID1 corresponds to the method described in Ref. [22]
bAMYLOID2 corresponds to the method described in Ref. [19]
cAMYLOID3 corresponds to the method described in Ref. [31]
Table 2: Comparison of AGGRESCAN predictions with the structural composition of different amyloid fibrils.
Protein Structure (β-strands) Prediction Reference
Aβ1-40 β 1: 12–24 17–22 [78]
β 2: 30–40 30–40
Amylin β 1: 12–17 13–18 [79]
β 2: 22–27 24–28
β 3: 31–37 - [80]
HET's Prion β 1: 226–234 -
β 2: 237–245 238–248
β 3: 262–270 263–267
β 4: 273–282 272–276
Mouse Prion (89–143) β 1: 112–124 115–129 [81]
β2- microglobulin (20–41) β 1: 21–30 22–30 [82]
β 2: 33–40 -
Transthyretin (105–115) β 1: 105–115 105–112 [83]Page 7 of 17
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area over the HS threshold (AAT) or in the area assigned
to the HS regions (THSA), are also informative. The nor-
malized values (relative to the number of residues) AATr,
THSAr and NHSA should be used if mutations resulting in
sequence deletions or insertions are considered. To asses
the capability of AGGRESCAN to predict sequence-varia-
tion effects we compared the experimentally observed
aggregation changes reported in the literature for a group
of more than 50 protein mutations with the change in dif-
ferent AGGRESCAN output variables. The analysis indi-
cates that Na4vSS is a good predictor for the effect on
aggregation propensity changes in the polypeptide
sequence on aggregation propensity (Table 4). The user
has to take into account that a given mutation in a short
protein is expected to have higher impact on aggregation
that the same change in a longer sequence, where its effect
can be more easily modulate by the rest of the sequence.
These considerations are already included in the calcula-
tion of the Na4vSS values.
The algorithm predicts accurately a large set of natural and
designed mutations of Aβ42 (the central hydrophobic
region of this peptide was used for the derivation of the
current a3v parameter set of AGGRESCAN) (Table 4). As
an example, Figure 3 shows how the F19T mutation,
which strongly decreases the deposition of Aβ42 [35],
results in the loss of the central HS in this peptide. Inter-
estingly, it also anticipates the lower aggregation propen-
sity of Aβ40 and the recent observation that longer
Aβisoforms possess increased aggregation propensities
[36]. Several natural occurring mutations have also been
shown to affect the aggregation rate of Tau [37-40]. The
predicted changes in the respective Na4vSS correlate well
with the experimental changes observed in these Tau var-
iants (Table 4). Figure 3 shows the Area plot of wild type
Tau and two of its mutants with highest, experimentally
tested, aggregation propensities. The P301L substitution
increases by 1,4 fold the area associated to the main "hot
spot" in Tau. In addition, AGGRESCAN predicts the pres-
ence of a new HS in the S320F mutant, absent in the wild
type form. This mutant is linked to tauthopaty, in which
Tau accumulates in inclusion bodies [40].
Other disease-related protein mutants studied here are the
recently described G4R and R68Stop of human Stefin B
protein. These mutants have been related with the devel-
opment of Myoclonus epilepsy of type 1. It has been
described that R68Stop is more prone to aggregate than
wild type Stefin, while the G4R mutant shows an opposite
behavior, with a slower fibril formation rate [41]. In agree-
ment with these experimental observations the algorithm
predicts an increase in the Na4vSS associated to the
R68Stop mutation and a decrease for the Gly4Arg change
(Table 4).
Type 1 serum amyloid A protein (SAA1) is associated with
Familial Mediterranean fever (FMF). FMF patients' geno-
types are thought to correlate with the different pheno-
types of the disease. A recent study [42] concludes that the
gamma SAA1 allele is more frequently observed in the
population devoid of amyloidosis, thus suggesting a pro-
tective effect of this allele on the development of the ill-
ness. In agreement with these results the AGGRESCAN
analysis of amyloid A sequence variants predicts that the
gamma variant misses a HS and has a lower Na4vSS than
other alleles.
The Src homology 3 (SH3) domain of the p58 subunit of
phosphatidyl-inositol-3 -kinase (PI3-SH3) is one of the
best-characterized examples of a small globular protein
unrelated to any known pathological condition that can
form amyloid fibrils in vitro [43]. Aggregated species
obtained from this protein have been found to be cyto-
toxic when added to cell cultures [44]. We have previously
shown that the α-spectrin-SH3 (SPC-SH3) domain, which
shares the same fold and 24% sequence identity with PI3-
SH3, is a soluble protein that does not form amyloid
fibrils under any conditions tested [45]. Nevertheless, a
recent work found that the N47A mutation at the distal
loop induces the formation of amyloid fibrils [46]. In con-
trast, the mutation of residue 47 to Gly does not promote
Comparative prediction performance of AGGRESCAN and structu e-based meth dsFigure 2
Comparative prediction performance of AGGRES-
CAN and structure-based methods. Comparative pre-
dictions of AGGRESCAN (solid circles), packing density 
profile [31] (no symbols), 3D Profile [32] using the 
NNQQNY template (solid squares) and 3D Profile using an 
ensemble of templates (empty squares). Predictions were 
tested in a Database of Fibril Formers and Non-Formers 
hexa-peptides. Predictions are shown as receiver-operator 
characteristic curves.Page 8 of 17
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Table 4: Comparison of the predicted and experimentally tested effects of mutations on the aggregation propensity of amyloidogenic 
proteins.
Sequence Name ∆Na4vSSa Experimentalb References
Peptide Aβ42 A21G -16 - [84]
Peptide Aβ42 E22K 15 + [84]
Peptide Aβ42 E22G 29 + [84]
Peptide Aβ42 E22Q 5 + [84]
Peptide Aβ42 F19P -68 - [85]
Peptide Aβ42 F19T -63 - [35]
Peptide Aβ42 D23N 16 + [86]
Peptide Aβ42 F19D -118 - [12]
Peptide Aβ42 I31L -15 - [87]
Peptide Aβ42 I32L -15 - [87]
Peptide Aβ42 I41G -62 - [87]
Peptide Aβ42 I41A -49 - [87]
Peptide Aβ42 I41L -12 - [87]
Peptide Aβ42 A42G -10 - [87]
Peptide Aβ42 A42V 32 + [87]
Peptide Aβ42 ∆ 1–4 59 + [88]
Peptide Aβ42 ∆ 1–9 237 + [88]
Peptide Aβ42 ∆ 40–42 -63 - [88]
Peptide Aβg∆ 41–42 -34 - [36]
Peptide Aβg5 89 + [36]
Peptide Aβg6 111 + [36]
Peptide Aβg7 167 + [36]
Peptide Aβ42 
V12E+V18E+M35T+I41N
-312 - [87]
Peptide Aβ42 F19S+L34P -123 - [87]
TAU R5L 2 + [89]
TAU R406W 2 + [90]
TAU G272V 2 + [90]
TAU Y310W 0 = [39]
TAU P301L 1 + [40]
TAU S320F 2 + [91]
α-synucleinA30P -1 = [92]
α-synucleinE46K 2 + [92]
α-synucleinA53T -1 + [92]
α-synucleinA76E -5 - [93]
α-synucleinA76R -3 - [93]
Amylin (Rat) R18H 9 + [94]
Amylin (Rat) L23F 17 + [94]
Amylin (Rat) V26I 11 + [94]
Amylin (Rat) R18H+L23F+V26I 34 + [94]
Amylin (human) (22–27) N22A 21 + [68]
Amylin (human) (22–27) F23A -59 - [68]
Amylin (human) (22–27)G24A 16 + [68]
Amylin (human) (22–27) I26A -61 - [68]
Amylin (human) (22–27) L27A -23 - [68]
Amylin (human) S20G -106 + [95]
Amylin (human) ProIAPP -90 +? [96]
Human PrP H111A 5 +/= [97]
Human PrP H111K 0 -/= [97]
Human PrP A117V 7 + [97]
Human PrP V210I 1 + [98]
Stefin R68X 37 + [41]
Stefin G4R -6 - [41]
SH3 n47a 17 + [46]
aRelative change in Na4vSS upon mutation, expressed as percentage.∆Na4vSS = ((Na4vSSmut - Na4vSSwt)/|Na4vSSwt|)*100
Na4vSSmut refers to the Na4vSS value of the mutant sequence.
Na4vSSwt refers to the Na4vSS value of the wild type sequence.
bChanges in aggregation determined experimentally.
Symbols: + increase; - decrease; = no significant change.
BMC Bioinformatics 2007, 8:65 http://www.biomedcentral.com/1471-2105/8/65
Page 10 of 17
(page number not for citation purposes)
Changes in the hot spot area plot caused by point mutations in amyloidogenic proteinsFigur  3
Changes in the hot spot area plot caused by point mutations in amyloidogenic proteins. a) Aβ42 wild type (red) 
and Aβ42 F19T mutant (green). b) SH3 wild type (red), SH3 D48G (green) and SH3 N47G (blue). c) TAU wild type (red), TAU 
P301L (green) and TAU S320F (blue).
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C
B
BMC Bioinformatics 2007, 8:65 http://www.biomedcentral.com/1471-2105/8/65aggregation (Ventura, S., unpublished results). According
to AGGRESCAN a new HS occurs in the amyloidogenic
mutant relative to both the wild type and N47G species,
which could be responsible for its increased aggregation
abilities (Figure 3).
Analysis of protein datasets
Besides analyzing the theoretical aggregation properties of
single molecules and their individual mutants, AGGRES-
CAN is also able to deal simultaneously with a large
number of sequences. This ability can be specially useful
to compare the global aggregation properties of different
protein sets and may help to delineate general rules
underlying the relationship between the primary structure
of proteins and peptides and their specific in vivo and in
vitro depositional properties. With this aim we studied the
correlation between the structural/aggregational features
of 5 different groups of proteins and the predictions pro-
vided by AGGRESCAN. These datasets were: 1) natively
globular proteins (160 proteins) (from SCOP, the
ASTRAL40 set); 2) natively intrinsically unstructured pro-
teins (51 proteins); 3) proteins which are soluble when
overexpressed in bacteria (38 proteins); 4) proteins form-
ing inclusion bodies when overexpressed in bacteria (121
proteins) and 5) amyloidogenic proteins (57 proteins)
(see additional file 4).
When average AGGRESCAN output values are calculated
and subsequently compared between data sets, it appears
that the different protein groups can be individualized
(Table 5), providing insight into the sequential determi-
nants of protein aggregation and solubility. In this way,
intrinsically unstructured proteins (IUP) clearly present
the lowest output values of all datasets, in correlation with
the general observation that unstructured proteins are
usually resistant to aggregation and remain soluble after
heat-treatment of the cells. Natively unfolded proteins
exhibit a Na4vSS value 7 times lower than that corre-
sponding to the set of globular proteins from SCOP. Also,
the normalized number of HS (NnHS) or the area over the
threshold (AAT) and total HS area (THSA) are around 2
times higher in globular proteins than in IUP, showing
that, in agreement with other automated analyses [47],
the number of aggregation-prone sequence stretches is
lower in IUP than in structured proteins. This result may
reflect a negative natural selection against aggregation
promoting residues and regions in IUP, where any HS will
be exposed to solvent and accessible for the establishment
of inter-molecular contacts that may finally lead to the
build-up of aggregates. For the same reason, nature is
likely to have provided globular proteins with a stable
native conformation in which aggregation-prone
sequences are buried in the inner hydrophobic core or
involved in intra-molecular interactions [13,18]. This
appears to be a successful evolutive strategy to avoid dep-
osition, since few proteins aggregate from their folded
state. Hence, amyloidogenic mutations in globular pro-
teins usually result in destabilization of the native state,
permitting exposure of natively hidden HS.
It has been recently shown that proteins that form inclu-
sion bodies (IB) upon recombinant overexpression in E.
coli and proteins that form amyloids in vivo and/or in vitro
share a good number of structural and functional features,
including high purity of the aggregates, enrichment in
beta-sheet structure, amyloid-tropic dye binding or
enhanced proteolytic resistance [3]. Comparison of the
two protein sets in search for similar trends in the predic-
tions showed that, unexpectedly, the AGGRESCAN values
for amyloid forming proteins are closer to those for IUP
than for any other of the analysed datasets. Amyloid pro-
teins have a lower Na4vSS and less HS than proteins in the
Table 5: Comparison of the different AGGRESCAN parameters for globular, natively unstructured, amyloidogenic, soluble and 
insoluble proteins.
Set Name Globular1 Unfolded2 Amyloid3 IBs4 Soluble5
a3vSA -0.04 -0.28 -0.12 -0.02 -0.05
nHS 9.54 5.63 5.86 11.97 10.34
NnHS 3.89 2.06 2.89 3.50 3.35
AAT 29.94 18.21 24.51 41.27 34.43
THSA 25.58 14.97 21.26 36.00 29.61
TA -5.17 -60.95 -26.42 -5.00 -5.55
AATr 0.12 0.07 0.13 0.13 0.12
THSAr 0.11 0.05 0.11 0.11 0.09
Na4vSS -4.26 -28.73 -12.96 -2.51 -5.18
In bold and italics are shown those parameters that are normalized by the number of residues, allowing direct comparison of datasets independently 
of protein size.
1Natively globular proteins: 160 proteins randomly selected from SCOP (the ASTRAL40 set)
2Natively intrinsically unstructured proteins: 51 proteins
3Amyloidogenic proteins: 57 proteins
4Proteins forming inclusion bodies when overexpressed in bacteria: 121 proteins
5Proteins which are soluble when overexpressed in bacteria: 38 proteinsPage 11 of 17
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BMC Bioinformatics 2007, 8:65 http://www.biomedcentral.com/1471-2105/8/65IB or globular SCOP dataset (Figure 4). In contrast, the
HSs in amyloid proteins comprise an area similar to those
in IB or globular proteins, which is, however, significantly
higher than the average HS area in IUP. These results sug-
gests that, globally, the sequences of amyloidogenic pro-
teins, like those of IUPs, have a low aggregation
propensity, although the existence of specific aggregation-
prone regions, absent or minor in IUPs, in a context in
which they can act as specific and obligatory nucleation
points from which the fibrillar structure could be
expanded, finally results in highly ordered aggregates (Fig-
ure 4). This would explain why point mutations in the
HSs of amyloidogenic proteins have usually a huge
impact in their solubility, as they would modify the prop-
erties of one of the few points in the sequence that can
promote and/or modulate aggregation. In contrast, the
paradoxically higher-ranking global aggregation propen-
sity of IB protein sequences is likely to indicate that here
HS would play a less important role, since aggregation can
also occur non specifically from many regions in the pro-
tein sequence. This would result in less structured depos-
its, and would also explain the rather moderate role of
point mutations in IB aggregate formation. In other
words, a given HS would promote specific amyloid forma-
tion in a low aggregating background, as its aggregation
tendency outstands from the rest of the sequence. Con-
versely, the same HS needs to compete with the rest of the
sequence to nucleate aggregation in a highly aggregating
context (Figure 5). For the same reason unstructured
aggregation is usually a much faster event than amyloido-
genesis. Recent theoretical and experimental data support
this view by showing that prevention of aggregation does
not necessarily mean that amyloid fibril formation is
abolished and vice versa [48]. This indicates that, despite
the fact that aggregates and amyloid fibrils share many
features, and the protein regions involved in their forma-
tion presumably intersect, they probably differ in the
number and specificity of intermolecular contacts
involved in the nucleation and stabilization of both types
of polypeptide associations.
Recombinant protein production is an essential tool for
the biotechnological industry and supports expanding
areas of basic and biomedical research, including struc-
tural genomics and proteomics. The solubility of proteins
expressed in bacteria under mass-production conditions
is of major concern, since many recombinant polypep-
tides produced in bacteria accumulate as insoluble, often
refractile, aggregates known as inclusion bodies (IBs)
[49], excluding many biotechnologically relevant protein
species from the market due to economically inconven-
ient yields. To date, the solubility of a given gene product
has not been anticipated before gene expression. The
comparison between the AGGRESCAN output values for
proteins shown to be soluble under overexpression condi-
tions in E. coli and those forming inclusion bodies shows
that they share a similar number of HSs per 100 residues
(NnHS), an expected output when considering that most
proteins in both datasets are globular. However, IB-form-
ing proteins have higher Na4vSS values than soluble pro-
teins, suggesting that soluble proteins have, on average, a
lower intrinsic aggregation tendency than IB-forming spe-
cies, which may determine, at least partially, their relative
behaviour upon overexpression. Overall, the predicted
aggregation of proteins in the SCOP database is interme-
diate between that of soluble and insoluble proteins, sug-
gesting that, in agreement with experimental
observations, only a part of them would remain in the sol-
uble cell fraction upon recombinant production.
Although AGGRESCAN is able to catch the average trends
in the aggregation of IBs and soluble protein groups, the
individual outputs for proteins from both groups overlap
significantly, making the prediction of the recombinant
behaviour of a given sequence difficult in its present form.
Besides, aggregation during recombinant production is
the net result of several extrinsic and intrinsic factors, their
relative importance depending on the protein and expres-
sion contexts.
Conclusion
The software and web interface developed in the present
study allow an easy and accurate identification and rank-
ing of aggregation-prone regions in polypeptides.
AGGRESCAN is also able to anticipate the effect of genetic
or artificially introduced sequence changes on the aggre-
gation properties of polypeptides. In addition to the
investigation of the role of the primary sequence on pro-
tein aggregation and protein solubility, the algorithm can
be used in the design of strategies for the treatment of
amyloidogenesis, by targeting therapies to those regions
in the polypeptide chain whose aggregation propensities
outstand from the rest, provided that they are or become
exposed to solvent in the disease-related protein confor-
mation. The surprising observation that the aggregation
propensities of amyloid sequences tend to be low, sug-
gests that blocking the "hot spots" of aggregation in these
proteins, either chemically or by mutation, may have a
huge impact on their solubility. Interestingly enough, pro-
tein-protein interactions are often mediated through an
energetic hot spot [50] which comprises few interface res-
idues that contribute to most of the binding energy; iden-
tification and blocking of those sequence stretches has
been suggested as an strategy to modulate protein interac-
tions [51]. The ability of AGGRESCAN to analyze simulta-
neously the aggregation properties of large sets of protein
sequences might be important for protein production in
large-scale structural initiatives, for the analysis of the dis-
tribution of aggregation-prone regions in complete
genomes or for evolutive studies, since it is likely that nat-Page 12 of 17
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"Hot spots" distribution in different protein groupsFigure 4
"Hot spots" distribution in different protein groups. Distribution of the number of "hot spots" relative to sequence 
length in the following protein datasets: natively globular proteins, intrinsically unstructured proteins, amyloidogenic proteins, 
soluble proteins when overexpressed in bacteria and proteins forming inclusion bodies when overexpressed in bacteria.
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Modulation of hot spot nucleation specificity by global aggregation propensityFigure 5
Modulation of hot spot nucleation specificity by global aggregation propensity. The black solid line represents a 
standard amyloidogenic protein aggregation profile, with only one "hot spot" and low global aggregation propensity. The pink 
discontinuous line corresponds to a typical aggregation profile from an inclusion-body-forming protein, with many "hot spots" 
and high global aggregation propensity. The horizontal lines represent the aggregation-propensity average thresholds for each 
sequence. The coloured regions indicate the area of each "hot spot" over the aggregation propensity threshold. It is proposed 
that a higher area over the threshold promotes a more specific aggregation reaction, resulting in highly ordered deposits.
Amino acid position
A
g
g
re
g
a
ti
o
n
 p
ro
p
e
n
s
it
y
BMC Bioinformatics 2007, 8:65 http://www.biomedcentral.com/1471-2105/8/65ural protein sequences have evolved in part to code for
avoidance of aggregation.
Availability and requirements
Project name: AGGRESCAN
Project home page: http://bioinf.uab.es/aggrescan/
Operating system(s): Platform independent
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Any restrictions to use by non-academics: Incorporation
into commercial products restricted.
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